Loading...
XTAI
4737
Market cap151mUSD
Jul 22, Last price  
72.70TWD
1D
-2.94%
1Q
33.64%
Jan 2017
30.05%
IPO
-28.03%
Name

Bionime Corp

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
2.30
EPS
—
Div Yield, %
2.75%
Shrs. gr., 5y
0.63%
Rev. gr., 5y
-2.31%
Revenues
1.93b
+10.15%
937,752,0001,211,743,0001,476,543,0001,435,022,0001,560,897,0001,524,669,0001,609,718,0001,740,309,0001,820,267,0002,007,222,0002,172,923,0001,668,586,0001,849,924,0002,210,589,0001,755,567,0001,933,746,000
Net income
-127m
L
135,237,000136,050,000179,111,00034,147,00089,929,00054,309,00098,793,000178,790,000149,608,000128,032,000106,258,00062,434,00087,413,00091,025,0006,209,000-127,216,000
CFO
20m
-90.40%
207,558,00013,661,000216,930,00023,575,000128,981,000359,843,000200,365,000457,836,00029,599,000121,898,000405,556,000217,556,000269,722,000142,292,000203,443,00019,530,000
Dividend
Jul 29, 20241.99997 TWD/sh

Profile

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.
URL
https://www.bionime.com/
IPO date
Aug 26, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,933,746
10.15%
1,755,567
-20.58%
2,210,589
19.50%
Cost of revenue
2,062,796
1,805,420
2,049,585
Unusual Expense (Income)
NOPBT
(129,050)
(49,853)
161,004
NOPBT Margin
7.28%
Operating Taxes
(59,712)
(38,406)
(5,337)
Tax Rate
NOPAT
(69,338)
(11,447)
166,341
Net income
(127,216)
-2,148.90%
6,209
-93.18%
91,025
4.13%
Dividends
(122,003)
(127,685)
(121,204)
Dividend yield
3.11%
2.79%
2.56%
Proceeds from repurchase of equity
6,929
10,464
9,319
BB yield
-0.18%
-0.23%
-0.20%
Debt
Debt current
1,587,208
1,119,851
779,545
Long-term debt
1,590,103
1,717,580
1,500,182
Deferred revenue
Other long-term liabilities
627
558
630
Net debt
2,689,932
2,389,794
2,029,138
Cash flow
Cash from operating activities
19,530
203,443
142,292
CAPEX
(186,084)
(293,081)
(312,921)
Cash from investing activities
(336,900)
(435,261)
(312,256)
Cash from financing activities
217,300
420,405
113,635
FCF
(105,194)
(94,864)
53,625
Balance
Cash
382,590
449,213
277,877
Long term investments
104,789
(1,576)
(27,288)
Excess cash
390,692
359,859
140,060
Stockholders' equity
634,278
761,443
1,217,165
Invested Capital
4,665,340
4,451,097
4,204,904
ROIC
4.10%
ROCE
3.71%
EV
Common stock shares outstanding
60,644
61,252
61,424
Price
64.70
-13.50%
74.80
-3.11%
77.20
1.85%
Market cap
3,923,647
-14.36%
4,581,650
-3.38%
4,741,933
2.85%
EV
6,622,617
6,978,614
6,779,182
EBITDA
53,755
113,569
314,236
EV/EBITDA
123.20
61.45
21.57
Interest
62,191
48,234
30,648
Interest/NOPBT
19.04%